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Vesicular Transport Regulates Monoamine Storage
and Release but Is Not Essential
for Amphetamine Action
activities use the Na1 gradient across the plasma mem-
brane to drive reuptake (Amara and Kuhar, 1993). In the
case of monoamines, cocaine and antidepressants act
by inhibiting plasma membrane transport, thereby in-
creasing the synaptic concentration of transmitter.
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mate (Schuldiner et al., 1995; Liu and Edwards, 1997).Columbia University
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transport relies on a proton electrochemical gradient
and in the case of monoamines involves the exchange
of two lumenal protons for one cytoplasmic monoamineSummary
(Johnson, 1988). Classic pharmacologic studies have
also indicated the potential for changes in vesicularTo assess the role of exocytotic release in signaling
monoamine transport to influence behavior. In contrastby monoamines, we have disrupted the neuronal
to cocaine and antidepressants, which inhibit plasmavesicular monoamine transporter 2 (VMAT2) gene.
membrane monoamine transport, reserpine and tetra-VMAT22/2 mice move little, feed poorly, and die within
benazine inhibit vesicular amine transport. Indeed, re-a few days after birth. Monoamine cell groups and
serpine very effectively lowers blood pressure by de-their projections are indistinguishable from those of
pleting the pool of stored monoamine. Reserpine alsowild-type littermates, but the brains of mutant mice
produces a syndrome resembling depression, givingshow a drastic reduction in monoamines. Using mid-
rise to the original hypothesis that monoamine transmit-brain cultures from the mutant animals, amphetamine
ters have a role in affective disorders (Frize, 1954).but not depolarization induces dopamine release. In
The action of amphetamines further indicates the po-vivo, amphetamine increases movement, promotes
tential for changes in both plasma membrane and vesic-feeding, and prolongs the survival of VMAT22/2 ani-
ular transport to influence transmitter release and be-mals, indicating that precise, temporally regulated
havior. Amphetamines promote flux reversal by plasmaexocytotic release of monoamine is not required for
membrane monoamine transporters, releasing cyto-certain complex behaviors. In addition, the brains of
plasmic transmitter through a nonexocytotic mecha-VMAT2 heterozygotes contain substantially lower
nism (Di Chiara and Imperato, 1988; Rudnick and Wall,monoamine levels than those of wild-type littermates,
1992; Sulzer et al., 1993; Giros et al., 1996). Neural activ-and depolarization induces less dopamine release
ity can also induce transmitter release by promoting fluxfrom heterozygous than from wild-type cultures, sug-
reversal through plasma membrane amino acid trans-
gesting that VMAT2 expression regulates monoamine
porters (Schwartz, 1987; Attwell et al., 1993), suggesting
storage and release.
a physiological as well as pharmacological role for this
form of nonvesicular release. In addition to their action
Introduction
at the plasma membrane, amphetamines induce mono-
amine efflux from vesicles (Sulzer and Rayport, 1990;
Synaptic transmission mediates the processing of infor-
Rudnick and Wall, 1992; Sulzer et al., 1995), increasing
mation in the central nervous system and involves the the amount of cytoplasmic transmitter available for ef-
rapid, precise exocytotic release of neurotransmitter flux from the cell. However, the role of a specific trans-
(Scheller, 1995; Sudhof, 1995). Although all of the classi- port protein in vesicular efflux and in the action of am-
cal transmitters undergo release by a similar exocytotic phetamines has remained unclear, since reserpine and
mechanism, the major inhibitory and excitatory transmit- tetrabenazine do not inhibit the efflux of monoamines
ters g-aminobutyric acid (GABA) and glutamate directly from chromaffin granules (Maron et al., 1983). Nonethe-
participate in information processing, whereas mono- less, the actions of both reserpine and amphetamines
amine transmitters such as dopamine, norepinephrine, indicate that interference with vesicular monoamine
and serotonin appear to modulate neural circuits. Similar storage has the potential to influence behavior.
to otherclassical transmitters, signaling by monoamines Molecular cloning has recently led to the identification
involves two distinct classes of transport activity. One of severalproteins involved invesicular neurotransmitter
class resides at the plasma membrane and removes transport. Selection of transfected cells for resistance
transmitter from the extracellular space, thereby termi- to the Parkinsonian neurotoxin 1-methyl-4-phenylpy-
nating its action. These plasma membrane transport ridinium (MPP1) yielded a cDNA encoding vesicular
monoamine transport, which protects against the toxin
by sequestering it inside secretory vesicles and away§To whom correspondence should be addressed.
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from its primary site of action in mitochondria (Liu et transfected cell clones resistant to the neomycin analog
G418, two showed homologous recombination at theal., 1992a, 1992b). The sequence predicts a polytopic
membrane protein with twelve transmembrane domains anticipated site in the VMAT2 gene by Southern analysis
using both 59 (Figure 1B) and 39 probes (data not shown).and no similarity to plasma membrane neurotransmitter
transporters (Erickson et al., 1992; Liu et al., 1992b). Injection of these ES clones into blastocysts yielded
multiple chimeras, and these were further bred withHowever, the sequence does show both structural and
functional similarity to a class of bacterial antibiotic re- C57BL/6 animals to produce VMAT2 heterozygotes
(1/2). The heterozygotes were then mated with eachsistance proteins, supporting a role in detoxification as
well as signaling. Indeed, the normal neurotransmitter other to produce homozygous (2/2) animals.
The knockout (2/2) mice lack VMAT2 by a variety ofdopamine readily oxidizes to produce free radicals and
may contribute to the selective degeneration of dopa- criteria. Western analysis using a polyclonal antibody
that we have raised to rat VMAT2 (Peter et al., 1995)mine cells that occurs in Parkinson's disease. Vesicular
monoamine transport may thus protect against this en- shows no detectable immunoreactive protein in mem-
branes prepared from the homozygotes (Figure 1C). Het-dogenous toxin as well as exogenous toxins such as
MPP1. The sequence also defined a family of proteins erozygotes contain less immunoreactivity, suggesting a
lack of compensation by the remaining normal allele, atthat now includes two vesicular monoamine transport-
ers (Erickson et al., 1992; Liu et al., 1992b) as well as least in terms of the level of protein. Other synaptic
vesicle proteins such as the vesicular acetylcholinean acetylcholine (ACh) transporter (VAChT; Alfonso et
al., 1993). Vesicular monoamine transporter 1 (VMAT1) transporter and synaptophysin show no generalized
reduction, confirming the specificity of the defect inoccurs in nonneural cells of the periphery, whereas
VMAT2 occurs in neurons (Weihe et al., 1994; Peter et VMAT2. To determine whether the gene disruption has
eliminated vesicular amine transport activity, we mea-al., 1995). Biochemical analysis of transport function in
transfected cells has also shown that the two VMATs sured transport in the knockout animals. Membranes
from VMAT22/2 mice show the same transport functiondiffer in their affinity for substrates, in their pharmacol-
ogy (Peter et al., 1994), and in their phosphorylation by as membranes from wild-type animals that have been
treated with the potent inhibitor reserpine, confirmingendogenous kinases (Krantz et al., 1997). Overexpres-
sion of VMAT2 in rat pheochromocytoma PC12 cells the loss of VMAT2 activity (Figure 1D). Importantly, the
results also indicate a lack of compensation by otherincreases quantal size z3-fold (Sun et al., unpublished
data). Similarly, overexpression of VAChT in cultured transport activities such as VMAT1, which occurs tran-
siently in the brain during development (Hansson et al.,Xenopus motor neurons increases quantal size 2- to
3-fold (Song et al., 1997), suggesting that the expression 1996, Soc. Neurosci., abstract). VMAT21/2 heterozygous
mice also show less transport activity than wild-typeof vesicular transporters determines the filling of synap-
tic vesicles and the amount of neurotransmitter re- animals,but the low concentrationsof 3H-serotonin used
for the assay do not provide a measure of the maximumleased.
To characterize the role of vesicular monoaminetrans- rate of transport (Vmax). To quantitate the reduction in
VMAT2, we measured binding to tetrabenazine, anotherport in transmitter release, signaling, and behavior in
vivo, we have disrupted the gene encoding the neuronal potent inhibitor of VMAT2 (Figure 1E). Brain membranes
from VMAT2 homozygotes show no specific binding toisoform VMAT2. The mutant mice move little, feed
poorly, and do not survive more than a few days after 3H-tetrabenazine, whereas heterozygotes show 52% of
the binding observed to membranes from wild-type lit-birth. However, amphetamines promote locomotion,
feeding, and survival, presumably by circumventing the termates.
Mice homozygous for disruption of the VMAT2 geneblock to exocytotic monoamine release. The precise
mode of monoamine release thus does not appear cru- are born from heterozygote crosses at the expected
Mendelian ratio of z1/4, indicating survival through em-cial for certain complex behaviors, consistent with the
role of monoamines as neuromodulators. The analysis bryonic development. However, VMAT22/2 animals show
differences from wild-type and heterozygous littermatesof VMAT2 heterozygotes also suggests that the expres-
sion of VMAT2 determines the rate of synaptic vesicle soon after birth. The homozygous animals are small and
move relatively little (Figure 2A). However, they do movefilling and the amount of monoamine released.
vigorously in response to mild pain (e.g., tail pinching),
excluding simple paralysis. Homozygous mice feed
Results poorly, with little if any milk visible in their stomachs,
do not gain weight (Figure 2B), and die within the first
To understand how vesicular transport influences week of life (Figure 2C).
monoamine release and behavior, we disrupted the To determine whether the elimination of VMAT2 im-
VMAT2 gene in mice. Transmembrane domain (TMD) pairs movement, feeding, and survival by interfering with
1 contains an aspartate required for transport activity neural development, we examined thebrains of homozy-
(Merickel et al., 1995). Since the first protein-coding gous knockout mice. Although smaller than those of
exon of the mouse VMAT2 gene encodes the entire wild-type littermates, the brains of VMAT22/2 animals
TMD1, we replaced this exon with a selectable marker show no gross disturbance in morphology. Staining with
for resistance to neomycin and introduced the con- cresyl violet also shows normal cell populations in the
struct, with 1.7 kb genomic DNA flanking the 59 end of forebrain and brainstem (data not shown). Since a distur-
the marker and 4.9 kb flanking the 39 end (Figure 1A), bance in monoamine transmission might have a rela-
tively selective effect on the development of monoamineinto 129/SvJ embryonic stem (ES) cells. From 400 stably
Amphetamine Rescues VMAT2 Knockout Mice
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Figure 1. Production of VMAT2 Mutant Mice
(A) Restriction maps of the native VMAT2 lo-
cus, targeting vector, and recombinant allele.
The boxes represent exons, with the open
section indicating untranslated sequence
and the filled section indicating protein-cod-
ing sequence. The arrow marks the site of
translation initiation. To construct the tar-
geting vector, the selectable marker for resis-
tance to neomycin PGK-neo was used to re-
place an Aat II-Pflm I restriction fragment that
contained the entire first protein-coding
exon. The location of 59 and 39 probes used
for genotype analysis (cross-hatched boxes)
are shown along with the predicted size of
Bam HI and Pflm I restriction fragments in the
wild-type (wt) and mutant alleles. The shaded
box indicates pBluescript vector sequences.
Restriction sites for Pflm I are indicated by
PI, sites for Bam HI by BI, Sac I by SI, Aat II
by AII, and Pst I by Pst.
(B) Southern analysis of genomic DNA from
the offspring of a cross between two VMAT2
heterozygous (1/2) mice. Tail genomic DNA
was digested with Pflm I, separated by elec-
trophoresis through agarose, blotted to ny-
lon, and hybridized to the 39 probe described
in (A). Both bands occur in the heterozygotes
(1/2), whereas only the 6.2 kb wt band ap-
pears in the wild-type (1/1) mice and only
the 11.2 kb mutant band in the homozygous
knockout (2/2) mice. Southern analysis was
also performed using digestion with Bam HI
and hybridizion with the 59 probe described
in (A) (data not shown). A total of 172 mice
born from crosses between VMAT2 heterozy-
gotes yielded the following genotypes: 1/1,
23.8%; 1/2, 49.4%; and 2/2, 26.7%.
(C) Western analysis of membrane vesicles
prepared by differential centrifugation from
the brains of wild type (1/1), heterozygous
(1/2), and knockout (2/2) mice. Membrane
vesicles from the brains of newborn mice (100
mg protein) were separated by electrophore-
sis through polyacrylamide and transferred
to nitrocellulose, and the blot was incubated
with the indicated antibodies. Incubationwith
the VMAT2 antibody shows no detectable im-
munoreactivity in knockout animals and reduced staining in heterozygous relative to wild-type mice. Staining with the antibodies against two
synaptic vesicle proteins, the vesicular acetylcholine transporter (VAChT) and synaptophysin (p38), shows no difference among VMAT21/1,
VMAT21/2, and VMAT22/2 animals.
(D) Transport of serotonin into membrane vesicles prepared by differential centrifugation from the brains of VMAT21/1, VMAT21/2, and VMAT22/2
mice (n 5 3 for each). Membrane vesicles (50 mg protein) were incubated in 20 nM 3H-serotonin at 298C for 2 min, a time at which the rate
of uptake remains maximal. Membranes from VMAT22/2 animals show the same activity as membranes from wild-type mice treated with 5
mM reserpine. The results are presented as the mean 6 standard error of the mean (SEM).
(E) Quantitation of VMAT2 protein by tetrabenazine (TBZ) binding to membrane vesicles prepared by differential centrifugation from the brains
of VMAT21/1 (n 5 4), VMAT21/2 (n 5 4), and VMAT22/2 (n 5 3) mice. Membrane vesicles (80 mg protein) were incubated in 5 nM 3H-
dihydrotetrabenazine at 298C for 20 min. The level of binding seen with knockout membranes does not exceed binding to wild-type membranes
in the presence of excess unlabeled TBZ (100 mM; n 5 4), confirming the absence of VMAT2 protein in the brains of the knockout mice.
Binding in the brains of VMAT21/2 animals was approximately half wild-type levels (51.8%; p , 0.001). The results are presented as the mean 6
SEM.
cell populations, we immunostained for tyrosine hydrox- et al., 1981; Fishell and van der Kooy, 1987) occur in both
wild-type and VMAT22/2 animals. Direct examination ofylase (TH), the rate-limiting enzyme in catecholamine
biosynthesis. Dopamine neurons in the substantia nigra the striatal patch-matrix system (Gerfen, 1992) by immu-
nostaining for the m opioid receptor also shows no differ-of VMAT22/2 mice (Figure 3B) show no clear difference
from those in wild-type animals (Figure 3A). In addition, ence between wild-type (Figure 3E) and knockout ani-
mals (Figure 3F). Thus, vesicular monoamine transportTH-immunoreactive fibers in the striatum of knockout
mice (Figure 3D) show no substantial difference from and hence exocytotic release of monoamines do not
appear to be required for normal development of thethose in wild-type littermates (Figure 3C). Dopamine is-
lands that form transiently during development (Graybiel mesostriatal projection.
Neuron
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Figure 3. Midbrain Dopamine Neurons and their Striatal Projections
in VMAT22/2 Mice
Coronal cryostat sections from the midbrain ([A] and [B]) and stria-
tum ([C] through [F]) of wild-type ([A], [C], and[E]) and VMAT2 knock-
out ([B], [D], and [F]) mice (n 5 3 for each) were stained with antibod-
ies to tyrosine hydroxylase (TH; [A] through [D]) and the m opioid
receptor ([E] and [F]). TH immunohistochemistry did not reveal any
major differences between the brains of VMAT21/1 and VMAT22/2Figure 2. Behavioral Phenotype of VMAT2 Mutant Mice
mice, either in terms of cell bodies ([A] and [B]) or their projections
(A) Appearance of 1-day-old wild-type and VMAT2 knockout mice.
([C] and [D]). In particular, both wild-type and knockout mice show
Compared to VMAT21/1 littermates, VMAT22/2 mice show little spon-
normal dendritic processes from the pars compacta of the substan-
taneous movement. Twenty-four hours after the placement of ink
tia nigra into thepars reticulata ([A] and[B]). Clustersof increased THmarks (white arrowheads) on both animals, the wild-type but not
staining in the striatum (ªdopamine islandsº) also showno differencethe VMAT22/2 mice have rubbed them off. In addition, the mutant
between wild-type and knockout mice ([C] and [D]). In addition,mice have little or no milk in their abdomens (black arrows), even
immunostaining using an antibody to the m opioid receptor ([E] andafter removal of wild-type and heterozygous pups from the litters
[F]) did not reveal any differences in the striatal patch-matrix systemto decrease competition for feeding.
between the wild-type and knockout mice. The arrows indicate(B) VMAT2 knockout mice do not gain weight. Animals from the
patches (striosomes) that are known to stain intensely with thissame litters (1/1, n 5 27; 1/2, n 5 45; and 2/2, n 5 20) were
antibody.weighed daily from P0 until the death of all VMAT22/2 mice.
Scale bars, 200 mm.(C) VMAT2 knockout mice show reduced survival. Intact litters were
monitored daily for survival (2/2, n 5 12; 1/2, n 5 15; 1/1, n 5
10). Removal of VMAT21/1 and VMAT21/2 littermates increased max- albeit considerably reduced from wild type (Figure 4C),
imum survival only slightly in remaining VMAT22/2 mice (to P10 ver- suggesting residual accumulation of cytoplasmic sero-
sus P8 in intact litters). tonin in cell bodies but not processes. We also quanti-
tated brain monoamines directly by high pressure liquid
To characterize the defect in monoaminetransmission chromatography (HPLC). The brains of homozygous
in VMAT22/2 mice, we examined brain monoamines di- mice show extremely low monoamines (Figure 4E), with
rectly. Immunostaining for serotonin revealed no detect- dopamine at z1.5% of wild-type levels, norepinephrine
able reactivity in the cortex of knockout mice (Figure at z6%, and serotonin at z1%. The results support the
4B), whereas wild-type animals contain profuse immu- previous impression that an extremely large proportion
noreactive fibers (Figure 4A). However, the cell bodies of brain monoamines in normal animals occurs in the
of serotonergic neurons in the raphe of VMAT22/2 homo- vesicular storage pool. The levels of dihydroxyphenyl-
acetic acid (DOPAC), homovanillic acid (HVA), andzygotes still contain some immunoreactivity (Figure 4D),
Amphetamine Rescues VMAT2 Knockout Mice
1275
Figure 5. Inhibition of Monoamine Oxidase Increases Serotonin but
Not Dopamine in VMAT22/2 Mice
Neonatal wild-type (1/1) and knockout (2/2) littermates were in-
jected subcutaneously with either saline, the MAO-A inhibitor clor-
gyline (10 mg/kg), or the nonselective MAO inhibitor pargyline (75
mg/kg). Two hours after administration, dopamine (DA) and seroto-
nin (5-HT) as well as their metabolites dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), and 5-hydroxyindolacetic acid
(5-HIAA) were measured in perchloric acid extracts prepared from
the brains of VMAT21/1 (n 5 9 for both saline and clorgyline, n 5 4
for pargyline) and VMAT22/2 (n 5 4 for each treatment) mice using
HPLC with electrochemical detection. Both clorgyline and pargyline
increased brain serotonin in VMAT22/2 mice (P 5 0.005 each) to
levels observed in saline-treated VMAT21/1 mice. In contrast, brain
dopamine levels do not increase in knockout animals after adminis-
tration of MAO inhibitors. Metabolism by MAO therefore accounts
for the low brain serotonin levels observed in the VMAT22/2 mice,
Figure 4. Reduced Brain Monoamine Levels in VMAT2 Mutant Mice whereas additional mechanisms maintain low brain dopamine lev-
(A±D) Coronal cryostat sections of the cerebral cortex ([A] and [B]) els. No major differences were observed for metabolite levels (data
and the brainstem raphe nucleus ([C] and [D]) in wild-type ([A] and not shown). The results are presented as mean 6 SEM.
[C]) and VMAT2 knockout ([B] and [D]) mice (n 5 3 for each) were
stained with an antibody to serotonin. The cortex of VMAT22/2 mice
(B) shows no immunoreactivity, whereas the cortex of VMAT21/1
(Chen and Shih, 1990). Clorgyline selectively inhibitsmice shows a rich network of reactive serotonergic fibers (A). The
MAO-A, the principal isoform found in newborn miceonly immunoreactive structures in VMAT22/2 mice were the cell bod-
ies of serotonergic neurons in the raphe nucleus (D). However, the (Cases et al., 1996). Injection of clorgyline into newborn
staining in this region was limited to cell bodies (D) and excluded wild-type mice increases dopamine only slightly but in-
from processes observed in VMAT21/1 mice (C). In addition, the creases serotonin by z2-fold (Figure 5). Injection into
intensity of staining of cell bodies in the raphe of VMAT22/2 mice
VMAT22/2 mice also has little effect on dopamine levelswas considerably less than that of VMAT21/1 littermates. Scale bar,
but increases serotonin towild-type levels. Thus, metab-100 mm.
olism by MAO-A accounts for the low levels of serotonin(E) Quantitation of monoamine and metabolite levels in VMAT2 mu-
tant mice. Dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in VMAT2 knockout mice. To determine whether MAO-B
as well as their metabolites, dihydroxyphenylacetic acid (DOPAC), accounts for the low levels of dopamine in VMAT2 mu-
homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5-HIAA) tant animals, we injected the relatively MAO-B±selective
were measured in perchloric acid extracts prepared from the brains
inhibitor pargyline, which also inhibits MAO-A at theof newborn VMAT21/1 (n 5 7), VMAT21/2 (n 5 14), and VMAT22/2
high doses that we used (Figure 5). However, similar to(n 5 9) mice using HPLC with electrochemical detection. Relative
clorgyline, pargyline increases only serotonin levels andto the brains of wild-type animals, the brains of knockout mice show
drastic reductions in the levels of dopamine (1.5%; p , 0.0001), has little effect on dopamine levels in both wild-type and
norepinephrine (6%; p , 0.001), and serotonin (1%; p , 0.0001). In mutant mice. Interestingly, both clorgyline and pargyline
contrast, metabolite levels appear similar in all groups. The brains increase the motor activity of knockout mice (data not
of the heterozygous mice also show reductions in dopamine (58%
shown), raising the possibility that dramatic elevationsof wild-type levels; p , 0.005) and 5-HT (66% of wild type levels;
in cytoplasmic transmitter induce release through a non-p , 0.01). The results are presented as mean 6 SEM.
exocytotic mechanism such as flux reversal by a plasma
membrane transporter.
To examine monoamine storage and release directly,5-hydroxyindolacetic acid (5-HIAA) appear normal in the
mutant mice (Figure 4E) despite the extremely low levels we used primary midbrain cultures. Although the knock-
out mice do not survive for more than a few days afterof monoamine transmitters, suggesting rapid metabo-
lism of the transmitter that cannot be stored in vesicles. birth, 4-week-old midbrain cultures from these animals
show numbers of TH-positive cells at least as greatTo assess the role of metabolism in the low mono-
amine levels of VMAT2-deficient mice, we have used as those from wild-type and heterozygous littermates
(Figure 6A). The morphology of dopamine neurons frominhibitors of monoamine oxidases (MAO) A and B, the
principal enzymes involved in monoamine degradation VMAT22/2 homozygotes also appears indistinguishable
Neuron
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from that of cells from normal littermates (Figure 6A).
Similar to monoamine levels in the brain, total dopamine
levels in the knockout cultures show a dramatic reduc-
tion (Figure 6B). To examine exocytotic release from the
midbrain cultures, we have used K1-evoked depolariza-
tion for 2 min and measured the dopamine released into
the medium. Whereas cultures from wild-type animals
show substantial release of dopamine, cultures from the
VMAT22/2 mice show essentially no release (Figure 6C),
confirming the requirement for vesicular transport to
enable exocytotic release of transmitter. We have also
used the midbrain cultures to determine the depen-
dence of amphetamine action on VMAT2. Exposure to
10 mM D-amphetamine for 30 min induces dopamine
release from the midbrain cultures of VMAT22/2 mice
(Figure 7A), indicating that VMAT2 is not required for the
action of this psychostimulant, at least in cells lacking
VMAT2. On the other hand, cultures from the knockout
animals release only z35% as much dopamine as cul-
tures from wild-type animals, demonstrating that VMAT2
and hence the vesicular pool nonetheless contribute the
majority of dopamine released by amphetamine. Inter-
estingly, the amount of dopamine not released by am-
phetamine (total minus released) appears to correlate
with VMAT2 gene dosage (Figures 7A and 7B), sug-
gesting that the transport activity also reduces net efflux
from vesicles.
Since VMAT2 gene disruption reduces total brain
monoamine and midbrain culture dopamine to ,5% of
wild-type levels, it is remarkable that amphetamine con-
tinues to induce release of greater than one-third as
much dopamine from the knockout cultures as from
wild-type cultures. Interestingly, amphetamine increases
the total amount of dopamine stored in and released
from midbrain cultures of wild-type mice by z2.5-fold
Figure 6. Primary Midbrain Cultures from VMAT2 Mutant Mice
relative to cells depolarized with K1 (Figure 7B), sug-
(A) Dopamine neurons from VMAT2-deficient mice survive in culture.
gesting that flux reversal across the plasma membrane Neurons derived from the midbrain of newborn VMAT21/1 and
promotes synthesis by reducing the feedback inhibition VMAT22/2 mice were grown in culture for 4 weeks and immuno-
stained for tyrosine hydroxylase (TH) (Mena et al., 1997). The TH-of cytoplasmic dopamine on TH (Zigmond et al., 1989;
immunoreactive cells from VMAT22/2 mice show no differences inKumer and Vrana, 1996). Strikingly, midbrain cultures
size, morphology, process number, or length from cells derived from
from VMAT22/2 homozygotes show a z30-fold increase VMAT21/1 animals. Cultures from VMAT22/2 mice contained at least
in total dopamine (stored and released) after exposure as many TH-positive cells (1277 6 41; n 5 2) as cultures from
to amphetamine relative to K1-evoked depolarization, VMAT21/2 (993 6 278; n 5 4) and VMAT21/1 (731 6 247; n 5 2)
animals. The results are presented as number of cells per plate 6presumably because the absence of a storage pool pre-
SEM. Scale bar, 50 mm.cludes vesicular efflux and, together with plasma mem-
(B) Accumulation of dopamine (DA) depends on VMAT2. Primary
brane efflux, essentially eliminates feedback inhibition cultures prepared from the midbrain of VMAT21/1 (n 5 11), VMAT21/2
on TH. The ability of amphetamine to induce substantial (n 5 9), and VMAT22/2 (n 5 6) mice were maintained in culture for
dopamine release from the VMAT2 knockout cultures 4 weeks. The sum of cellular and extracellular medium dopamine,
as measured by HPLC coupled with electrochemical detection, wasalso suggests a way to assess the effects of nonvesicu-
used to determine total dopamine in unstimulated cultures. Cultureslar monoamine release in vivo.
from knockout mice show a marked reduction in total dopamine,Since amphetamine appears able to circumvent the containing 1.7% the levels of wild-type cultures (p , 0.00001). Cul-
defect in exocytotic monoamine release from VMAT2 tures from heterozygous mice contain 73.6% the dopamine of wild-
mutant cultures, we determined whether D-amphet- type cultures (p , 0.05). The results are presented as mean 6 SEM.
(C) Depolarization-evoked release of dopamine (DA) depends onamine (10 mg/kg, subcutaneously) would improve the
VMAT2. Primary cultures prepared from the midbrains of VMAT21/1,feeding behavior of mutant animals.One hour after injec-
VMAT21/2, and VMAT22/2 mice (n 5 4 for each) were maintained in
tion with D-amphetamine, a large proportion of VMAT22/2 culture for 4 weeks and stimulated with 40 mM KCl for 2 min, and
animals were either actively suckling or had milk in their the dopamine (DA) released into the medium was measured by
stomachs (Figure 8A). In contrast, uninjected or saline- HPLC. Cultures from knockout mice release only 3.9% of the dopa-
mine released by wild-type cultures (p , 0.005). Cultures from het-injected mice showed very little feeding. To confirm that
erozygous mice also release less dopamine than wild-type culturesamphetamine action involved the nonvesicular release
in response to KCl-evoked depolarization (46.8%; p , 0.01). Theof monoamine through flux reversalmediated by plasma difference between wild-type and heterozygous cultures in terms
membrane transporters, we also injected the catechola- of depolarization-evoked dopamine release thus exceeds the differ-
mine transport inhibitor nomifensine. Nomifensine se- ence in dopamine levels betweenthese cultures when not stimulated
(73.6%; Figure 6B). The results are presented as mean 6 SEM.lectively inhibits the reuptake of catecholamines and
Amphetamine Rescues VMAT2 Knockout Mice
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at http://www.neuron.org/supplemental/19/6/1271), feed
better, and increase slightly in weight. Although they
never attain the same weight as wild-type or heterozy-
gous littermates and eventually die, amphetamine injec-
tion clearly increases the survival of VMAT22/2 animals
into the third week after birth. Amphetamine can thus
circumvent the defect in vesicular release of monoamine
transmitters and promote complex behavioral phenom-
ena such as locomotion and feeding, but it does not
restore the knockout mice to normal.
We have also analyzed VMAT21/2 heterozygotes to
determine how the level of transporter expression influ-
ences transmitter release and behavior. The heterozy-
gotes appear indistinguishable from wild-type litter-
mates throughout the period of observation. Indeed,
they move vigorously, feed well, and grow normally (Fig-
ures 2B and 2C). However, VMAT21/2 heterozygotes
contain 58% as much dopamine, 77% as much norepi-
nephrine, and 66% as much serotonin as wild-type ani-
mals (Figure 4E), indicating that a 50% reduction in
VMAT2 protein expression produces a large reduction
in monoamine stores. VMAT2 thus regulates the amount
of neurotransmitter stored in vivo. In addition, midbrain
cultures from heterozygous mice contain only z75% as
much dopamine as cultures from wild-type littermates
and release 47% as much dopamine in response to
depolarization for 2 min with elevated K1 (Figures 6B
and 6C). The regulated release of dopamine during con-
tinuous stimulation thus depends on VMAT2 expression,
suggesting that VMAT2 determines the filling of recy-
cling synaptic vesicles. If VMAT2 regulates the rate ofFigure 7. Amphetamine Induces Release in the Absence of Vesicu-
lar Transport refilling, this would predict that changes inneural activity
(A) Amphetamine induces release in cultures from VMAT22/2 mice. and hence vesicle cycling would alter the amount of
Primary cultures prepared from the midbrains of VMAT21/1, transmitter stored per vesicle.
VMAT21/2, and VMAT22/2 mice (n 5 4 for each) were maintained in
culture for 4 weeks and stimulated with 10 mM D-amphetamine for
30 min, and the dopamine (DA) released into the medium was mea- Discussionsured by HPLC. Amphetamine induces the release of 35.8% as
much dopamine in the VMAT22/2 as in VMAT21/1 cultures (p ,
Disruption of the VMAT2 gene in mice has dramatic0.001). The results are shown as the mean 6 SEM.
(B) Amphetamine produces a greater increase in dopamine levels consequences for the survival of the organism. Despite
in cultures from VMAT22/2 mice than in those from VMAT21/1 or transient expression of the nonneural isoform VMAT1 in
VMAT21/2 animals. Total dopamine was measured by adding the neurons during embryonic development (Hansson et al.,
values for intracellular dopamine to the values for released dopa-
1996, Soc. Neurosci., abstract), VMAT22/2 mice showmine in 4-week-old primary cultures generated from the midbrains
no vesicular monoamine transport activity in the brain asof knockout, heterozygous, and homozygous mice (n 5 4 for each)
early as 1 day after birth. In addition, VMAT21/2 animalsafter stimulation with either 40 mM KCl or 10 mM D-amphetamine.
Amphetamine increases dopamine levels 30-fold more than stimula- show little evidence of compensation by the intact allele.
tion with KCl in the knockout cultures, but only z2.5-fold more than The brains of heterozygous mice contain substantially
KCl in the wild-type and heterozygous cultures. The results are less VMAT2 protein than wild-type mice by Western
presented as mean 6 SEM.
analysis and z50% as much binding to 3H-tetrabena-
zine. The failure to observeeither compensatory upregu-
lation of VMAT1 in the absence of VMAT2 or of thestrongly reduces the effect of amphetamine on feeding
(Figure 8A). Thus, the nonvesicular release of catechola- remaining wild-type allele in the heterozygotes suggests
that cell identity rather than monoamine neurotransmis-mine promoted by amphetamine can sustain certain
complex behaviors in the absence of exocytotic release. sion determine both the isoform and level of VMAT ex-
pressed.Since poor feeding and reduced growth presumably ac-
count for the failure of VMAT22/2 mice to survive, we The absence of exocytotic monoamine release in
VMAT22/2 mice has no discernible effect on brain devel-then injected the knockout mice with the same dose of
D-amphetamine three times a day. As shown in Figure opment. The animals areborn in theexpected Mendelian
proportions from heterozygote crosses and standard8B, knockout animals injected with amphetamine sur-
vive substantially longer than knockout mice injected histological stains reveal no major abnormality in brain
structure. Further, immunostaining of the brainstem forwith saline. Indeed, they move more, show more di-
rected movements such as crawling in the first week TH shows abundant catecholamine neurons with normal
morphology. Mesostriatal dopamine projections alsoand walking in the third week (see supplemental video
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has no effect on their appearance, strongly suggesting
their independence of monoamine neurotransmission,
unless VMAT1 compensates for the absence of VMAT2
during a critical period early in embryonic development
(Hansson et al., 1996, Soc. Neurosci., abstract). Consis-
tent with the observed independence from vesicular
monoamine transport, dopamine-deficient mice also
show normal development of dopamine neurons and
their striatal projections (Zhou and Palmiter, 1996). The
formation of monoamine connections may thus depend
either on signaling by transmitters other than mono-
amines or on intrinsic developmental mechanisms.
Although the brain appears to develop normally in
VMAT2 mutant mice, the animals survive for only a few
days after birth. Nonetheless, they still live longer than
mice deficient in TH that cannot produce catechola-
mines and mice deficient in dopamine b-hydroxylase
that cannot produce norepinephrine, which largely die
in utero. (Thomas et al., 1995; Zhou et al., 1995). Since
elimination of vesicular transport also interferes with the
release of catecholamines, the ability of VMAT2 mutants
to survive past birth suggests that these transmitters
are released through a different mechanism, possibly
through VMAT1 expression, which persists into adult-
hood in nonneural cells such as chromaffin cells of the
adrenal medulla (Weihe et al., 1994; Peter et al., 1995).
In contrast, the biosynthetic enzymes occur as only a
single isoform, resulting in catecholamine dysfunction
in both neural and nonneural tissues of knockout mice.
Indeed, the embryonic lethality of knockouts in the bio-
synthetic enzymes may result from a disturbance in the
peripheral cardiovascular system (Thomas et al., 1995;Figure 8. Behavioral Effects of Amphetamine in VMAT2-Deficient
Mice Zhou et al., 1995) rather than the brain. On the other
(A) Acute effect of amphetamine (AMPH) on feeding behavior hand, VMAT22/2 animals do not survive as long as dopa-
in VMAT22/2 mice. D-amphetamine (10 mg/kg, subcutaneously), mine-deficient mice (Zhou and Palmiter, 1996). The be-
D-amphetamine coadministered with the plasma membrane uptake havioral deficit in VMAT2 mutant mice resembles that
inhibitor nomifensine (10 mg/kg), and normal saline were alternately
observed at a slightly greater age in dopamine-deficientadministered to neonatal VMAT22/2 mice (n 5 28). The injections
animals, with reduced movement and feeding behavior,were initiated within 24 hr after birth and repeated twice daily for
supporting the results of classic pharmacological stud-up to 7 days after birth. One hour after administration, the mice
were scored for either active suckling or the presence of milk in the ies showing that dopamine stimulates locomotion and
stomach. Feeding behavior was greatly enhanced by amphetamine mediates the rewarding action of food (Wise, 1990;
compared to saline. This increased feeding was blocked by the
Koob, 1992). However, the requirement of VMAT2 func-specific plasma membrane catecholamine transport inhibitor nomi-
tion for norepinephrine and serotonin as well as dopa-fensine.
mine release from neural cells may account for onset(B) Amphetamine increases survival in VMAT2-deficient mice. At
birth, VMAT22/2 mice were alternately assigned to receive either of the syndrome immediately after birth in the VMAT2
D-amphetamine (AMPH; 10 mg/kg, subcutaneously; n 5 13) or nor- mutants rather than at 2 weeks as in the dopamine-
mal saline (n 5 13), both administered three times per day. Half the deficient mice.
mice that had received amphetamine survived to the third week
The dramatic reduction in brain monoamines ob-after birth, whereas none of the mice who had received saline sur-
served in VMAT2-deficient animals reflects the absencevived past the first week. Mean survival also increased from 3.2 6
0.5 days in the saline-treated to 10.7 6 1.8 days in the amphetamine- of a storage pool and supports previous work sug-
treated animals (p , 0.001). Amphetamine increased spontaneous gesting that the bulk of brain transmitter resides in syn-
activity and weight as well, with saline-treated mice reaching 1.36 6 aptic vesicles. Nonetheless, the level of monoamine me-
0.05 g, whereas amphetamine-treated littermates reached 2.26 6
tabolites remains similar to that of wild-type animals.0.23 g (p , 0.001).
The relatively high level of metabolites suggests that
the failure to package transmitter into synaptic vesicles
increases the time spent in the cytoplasm and hence theappear normal, including the presence of dopamine is-
accessibility to enzymes such as monoamine oxidaselands (Graybiel et al., 1981; Fishell and van der Kooy,
(Napolitano et al., 1995). Indeed, inhibition of MAO-A1987) and m opioid receptor-positive patches (Gerfen,
increases serotonin levels dramatically inVMAT2 knock-1992). Although these structures presumably reflect
out mice, indicating a central role for MAO-A in thefinely tuned mechanisms that govern the development
of striatal circuitry, the absence of dopamine release metabolism of serotonin. The increased immunoreactive
Amphetamine Rescues VMAT2 Knockout Mice
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serotonin in cell bodies but not processes of raphe neu- amphetamine to induce substantial dopamine release
even in the absence of vesicular stores. Amphetaminerons in untreated VMAT22/2 mice may result from re-
duced metabolism at this site (Westlund et al., 1988; thus appears to have a greater effect on dopamine syn-
thesis when the vesicular store of transmitter is de-Saura et al., 1992) or by less prominent feedback inhibi-
tion of tryptophan hydroxylase (Boadle-Biber, 1993). pleted, possibly because the reduced efflux from vesi-
cles together with increased efflux across the plasmaHowever, dopamine levels do not increase even after
inhibition of both MAO-A and -B, suggesting that addi- membrane reduces cytoplasmic concentrations to ex-
tremely low levels and essentially eliminates feedbacktional mechanisms prevent accumulation. The absence
of an increase in metabolites in VMAT22/2 mice over wild inhibition on the rate-limiting biosynthetic enzyme TH
(Zigmond et al., 1989; Kumer and Vrana, 1996). In addi-type suggests a down-regulation of biosynthesis due to
feedback inhibition of TH (Spector et al., 1967), although tion, the absence of vesicular monoamine transport may
cause the accumulation of cytoplasmic transmitter toan overall increase in metabolic flux through the path-
way is also possible. Indeed, the increased cytoplasmic levels that promote efflux across the plasma membrane.
Amphetamine action may thus require vesicular storesconcentrations of monoamine may promote nonvesicu-
lar release by the reversal of plasma membrane trans- and hence VMAT2 function in wild-type animals to ele-
vate cytoplasmic monoamines and promote efflux.porters even in the absence of drugs such as amphet-
amine. The increased motor activity observed after Nonetheless, the extraordinary ability of amphetamines
to induce release even in the absence of vesicular storesadministration of theMAO inhibitors supports this possi-
bility. may account for persistent effects even after repeated
administration and hence underlie their potential forA variety of conditions such as disruption of the
plasma membrane dopamine transporter dramatically abuse (Robinson, 1991; Seiden et al., 1993; Pierce and
Kalivas, 1995; Melega et al., 1995).reduce brain monoamines but do not impair survival
(Giros et al., 1996), suggesting that VMAT2 disruption The ability of amphetamine to induce dopamine re-
lease from VMAT2-deficient neurons also enabled us toblocks monoamine release as well as reduces stores.
Using primary midbrain cultures, K1-evoked depolariza- assess the biological effects of nonvesicular release.
Administration of L-DOPA to patients with Parkinson'stion induces release of dopamine from wild-type but
not from homozygous mutant cultures, confirming the disease has suggested that tonic rather than phasic
release of dopamine may suffice to preserve motor con-requirement of vesicular transport for exocytotic re-
lease. Amphetamine continues to induce dopamine re- trol (Birkmayer and Hornykiewicz, 1961; Cotzias et al.,
1969). However, the dopamine derived from exogenouslease from mutant cultures, indicating that the expres-
sion of VMAT2 and the presence of vesicular stores is L-DOPA presumably enters the remaining dopamine ter-
minals from which it undergoes exocytotic releasenot required for this in vitro measure of drug action, at
least in VMAT2-deficient cells. (In wild-type cells, VMAT2 (Pothos et al., 1996). The progressive loss of dopamine
neurons in the disease and the reduced ability to storemay be essential to promote vesicular efflux, increase
cytoplasmic monoamine, and so promote efflux across and release dopamine in a regulated manner may indeed
underlie the eventual failure of L-DOPA replacementthe plasma membrane.) In cells lacking VMAT2, flux re-
versal by plasma membrane monoamine transporters therapy (Brannan et al., 1996). To determine whether
tonic monoamine release can support complex behav-apparently suffices to mediate the release of mono-
amines by amphetamine, consistent with both pharma- ioral phenomena, we took advantage of the ability of
amphetamine to induce nonvesicular monoamine re-cologic and genetic studies (Di Chiara and Imperato,
1988; Rudnick and Wall, 1992; Sulzer et al., 1993; Giros lease in the absence of VMAT2. Systemic administration
to newborn VMAT22/2 mice increases directed locomo-et al., 1996). Nonetheless, the amount of dopamine re-
leased by amphetamine from the mutant cultures was tor behavior, including crawling in the first few days
after birth and walking in the third week. In addition,z35% that released from wild-type cultures, indicating
that the majority of dopamine is released from the vesic- amphetamine increases suckling and the presence of
milk in theabdomen. The catecholamine reuptake inhibi-ular compartment, at least under normal conditions (Flo-
rin et al., 1995; Sulzer et al., 1996). The observation that tor nomifensine blocks these phenomena, indicating
that nonvesicular release through a plasma membranethe amount of dopamine not released by amphetamine
also correlates with VMAT2 gene dosage may indicate transporter can induce certain complex behaviors and
phasic release is not required for these phenomena. Thethat VMAT2 actually opposes the action of amphet-
amine, although residual lumenal dopamine bound to a ability of nomifensine to block amphetamine stimulation
of these behaviors also strongly suggests that they arematrix inside the vesicle could limit vesicular efflux in
wild-type and to a lesser extent heterozygous mice. mediated by catecholamines. Clorgyline stimulates sim-
ilar behaviors to amphetamine but elevates only seroto-In light of the drastically reduced dopamine stores
observed in both the brains and cultures of VMAT22/2 nin. However, catecholamine efflux induced by clorgy-
line may not result in a net increase in steady-state levelsmice, the ability of amphetamine to release relatively
large amounts of dopamine is remarkable. Midbrain cul- due to metabolism unrelated to MAO.
Although amphetamine prolongs the survival oftures from both wild-type and mutant mice show an
increase in dopamine after exposure to amphetamine VMAT2 mutant mice, they still do not grow normally and
die in the third week of life. The inability of amphetaminerelative to depolarization. However, the increase in mu-
tant cultures is 10-fold greater than the increase in wild- to rescue the VMAT2-deficient phenotype completely
may result from insufficiently frequent administration,type cultures, apparently accounting for the ability of
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reduced efficacy with repeated use, or the inadequacy These results support recent studies of vesicular ace-
tylcholine transport in a culture model of the neuromus-of nonvesicular monoamine release to sustain more
complex behaviors required for survival beyond 2±3 cular junction. In this system, elevated expression of
VAChT increased quantal size (Song et al., 1997), pre-weeks of age. It also remains unclear whether amphet-
amine improves viability by releasing monoamines from sumably because this protein also influences the rate
of synaptic vesicle filling. The expression of vesicularcentral or peripheral sympathetic stores. Nonetheless,
the ability to prolong survival of VMAT22/2 animals into neurotransmitter transport proteins thus limits vesicle
filling in the presence of wild-type as well as reducedthe third week after birth should enable analysis of such
postnatal developmental events as barrel field forma- transporter expression. This predicts that changes in
activity and hence vesicle cycling will influence thetion, in which the plasma membrane serotonin trans-
porter and VMAT2 have both been implicated (Lebrand amount of transmitter stored per vesicle. Elevated
VAChT expression also increased the frequency of re-et al., 1996).
In addition to its essential role in exocytotic release, lease (Song et al., 1997), possibly because the larger
quantal size facilitated detection. However, increasedthe level of VMAT2 expression influences the amount
of monoaminestored and released. Although the VMAT2 VAChT may also recruit synaptic vesicles not previously
capable of storing neurotransmitter, a possibility sup-heterozygotes appear normal in behavior, growth and
survival, their brains contain substantially less dopamine ported by the observation that unstimulated wild-type
midbrain cultures store substantially more dopamineand serotonin than wild-type animals. VMAT2 thus de-
termines the storage of these transmitters. If synaptic than VMAT2 heterozygote cultures even though the un-
stimulated state should permit greatly increased timevesicles have adequate time to fill with neurotransmitter,
the level of VMAT expression should make little differ- for vesicle refilling.
In summary, the results show that VMAT2 is essentialence to the amount of transmitter stored at equilibrium.
However, if synaptic vesicles do not have adequate time for exocytotic monoamine release but not release in-
duced by amphetamine, at least in the absence of vesic-to fill, VMAT2 expression would influence the amount
of transmitter stored. ular monoamine stores. Indeed, amphetamine partially
rescues the phenotype of VMAT2-deficient mice, indi-Recent studies have demonstrated rapid recycling of
synaptic vesicles within 1±2 min after exocytosis (Ryan cating that nonvesicular release suffices for behavior
dependent on monoamines, consistent with their roleet al., 1993; Lagnado et al., 1996). If eachsynaptic vesicle
contains z5000 molecules of serotonin (Brunsand Jahn, as neuromodulators. The analysis of heterozygous mice
also demonstrates that the level of VMAT2 expression1995), it would take a single VMAT2 protein with a turn-
over number of 5/s at 298C (Peter et al., 1994) z15 influences the storage and release of monoamines, pre-
sumably because the rate of synaptic vesicle recyclingmin to fill the vesicle at saturating concentrations of
transmitter. Although the rate would be greater at 378C, exceeds the rate of refilling with transmitter but possibly
because transporter expression also determines theand the turnover of dopamine by VMAT2 is faster than
that of serotonin (Finn and Edwards, 1997), the filling number of vesicles capable of storing transmitter.
would still take several minutes at saturating substrate
concentrations. In addition, the cytoplasmic concentra- Experimental Procedures
tion of monoamines appears considerably lower than
Production of VMAT2 Mutant Micethe Km for transport (Perlman and Sheard, 1982), making
Using the rat VMAT2 cDNA as a probe for hybridization, severalthe time required to fill the vesicle considerably longer.
phage clones were isolated from a mouse 129/SvJ strain genomicIndeed, the release of 47% as much dopamine by het-
library. Restriction and Southern analysis identified a 7.5 kb frag-
erozygote VMAT21/2 cultures as by wild type suggests ment containing the first and second protein-coding exons. After
that synaptic vesicles do not have adequate time to fill. subcloning into pBluescript (Stratagene), a 0.9 kb Aat II-Pflm I frag-
ment containing the entire firstprotein-coding exon was excised andUnstimulated midbrain cultures show little spontane-
replaced with a 1.3 kb selectable marker for resistance to neomycinous activity and hence should allow sufficient time for
(PGK-neo). The resulting 11 kb targeting vector thus contained thevesicle filling. It is therefore surprising that heterozygote
inserted PGK-neo cassette flanked on the 59 side by 1.7 kb and oncultures contain only z75% as much dopamine as wild
the 39 side by 4.9 kb of genomic VMAT2 sequence.
type. This raises the possibility that VMAT2 expression Strain 129/SvJ ES cells were grown in the presence of leukemia
does not influence solely the rate of filling but also the inhibitory factor (LIF) on a monolayer of neomycin-resistant, g-irradi-
number of vesicles that can be filled. The VMATs are ated, mouse primary embryonic fibroblasts. The targeting vector
was linearized by digestion with Sal I, and 20 mg DNA was introducedexpressed at low levels relative to other synaptic vesicle
into 2 3 107 ES cells by electroporation at 250 V and 500 mF. Afterproteins and may not occur in all synaptic vesicles.
selection for 10 days in the neomycin analog G418 (effective dose,Changing the level of expression may thus alter the
250 mg/ml), resistant colonies were picked and transferred to micro-
number of vesicles available for release as well as the titer plates. The colonies were grown for an additional 4 days and
amount of transmitter per vesicle. The level of norepi- then split into duplicate plates, with one used to prepare genomic
nephrine in the brains of heterozygous mice approaches DNA and the other to propagate the clones. Southern analysis of
genomic DNA digested with Pflm I and hybridized with a 1.3 kb Pstthat of wild-type animals, suggesting that VMAT2 may
I-Pflm I fragment from genomic DNA flanking the 39 end of thenormally occur at higher levels in noradrenergic neu-
targeting vector identified 2 out of 400 G418-resistant colonies withrons, so that heterozygous levels still suffice to ensure
an enlarged 11.2 kb Pflm I fragment as well as the wild-type 6.2 kb
adequate rates of refilling or at least one transporter per allele. Southern analysis with a probe flanking the 59 end of the
vesicle. Alternatively, lower levels of activity in these targeting vector confirmed the presence of homologous recombina-
cells may not require high rates of vesicle recycling and tion in these two cell clones (data not shown).
Both ES cell clones demonstrating homologous recombination athence refilling.
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the VMAT2 locus were microinjected into C57BL/6 blastocysts. Male Histology
Mice aged 0±7 days after birth were anesthetized and perfusedchimeras derived from these blastocysts were mated with C57BL/6
females and germline transmission was assessed by coat color. Tail for 15 min with cold 4% paraformaldehyde±4% sucrose in 0.1 M
phosphate buffer (pH 7.4). The brains were then dissected and im-genomic DNA was used to genotype the agouti offspring, either by
Southern analysis using the 39 probe described above or by PCR. mersed in the same fixative overnight at 48C, cryoprotected in in-
creasing concentrations of sucrose (10%, 20% and 30%), frozen inOne pair of primers (59-CATCGTGTTCCTCGCGCTGC-39 and 59-
GGGATGCTGTCACCTGGG-39) was designed to amplify a 181 bp O. C. T. (Tissue-Tek), and sectioned at 15±30 mm using a cryostat.
All histologic analysis involved comparison of VMAT22/2 mice withfragment in the wild-type butnot themutant allele,whereas a second
primer pair (59-CCGCTCCCGATTCGCAGCG-39 and 59-GCAGCAGC wild-type (1/1) mice from the same litter.
For immunocytochemistry, brain sections were rinsed in phos-TTAGCACACTGG-39) was designed to amplify a 292 bp fragment
in the mutant but not the wild-type allele. Heterozygous mice were phate buffered saline (PBS), pretreated with 0.3% H2O2 in PBS for
30 min, blocked in PBS containing 5% normal goat serum and 0.3%then mated to generate homozygous mutant mice.
Triton X-100 for 1 hr, and then incubated at 48C overnight in the
same buffer with either antibodies to TH (Eugene Tech), m opioidWestern Analysis
receptor (a generous gift of Chris Evans, UCLA), or serotoninTo prepare membrane vesicles, the brains of newborn mice were
(Incstar) at dilutions of 1:1000, 1:100, and 1:25,000, respectively.dissected on ice, frozen immediately, and stored in liquid nitrogen.
After washing in PBS containing 1% normal goat serum and 0.3%Using a chilled porcelain mortar and pestle, the brains were ground
Triton X-100 (PBT) three times for 10 min each, the sections wereto a fine powder and dissolved in z5 ml cold 0.32 M sucrose, 10
incubated for 30 min at room temperature with biotinylated goatmM HEPES-KOH (pH 7.4; SH buffer) containing 5 mM Mg EGTA,
anti-rabbit secondary antibody (Vector) diluted 1:200 in PBT,0.4 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin, 2 mg/ml
washed three times again in PBT, and incubated for 30 min with anpepstatin A, 2 mg/ml E64, and 2 mg/ml aprotinin (homogenization
avidin-biotin complex conjugated to horseradish peroxidase (Vec-buffer). The samples were then disrupted with a Teflon homogenizer
tor), again in PBT. The sections were then washed twice in PBT andand the debris sedimented at 1600 3 g for 10 min at 48C. Membrane
once in PBS, and the deposits were visualized with 0.04% 39,39-vesicles in the supernatant were then collected by sedimentation
diaminobenzidine and 0.0001% H2O2, using 0.3% NiSO4 to enhanceat 175,000 3 g for 1 hr at 48C. The pellet was resuspended in z200
the reaction.
ml homogenization buffer and either used immediately or stored at
2708C. The protein concentration of the sample was determined
using the Bradford assay (Bio-Rad). Quantitation of Brain Monoamines
For Western analysis, 100 mg membrane protein extracted from Whole brains from neonatal mice were dissected on ice and dis-
the brains of wild-type, heterozygous, and homozygous mice was rupted with a Teflon homogenizer in 1 ml cold 0.1 N perchloric acid
separated by electrophoresis through 10% polyacrylamide and and 0.1 mM EDTA. The extracts were then sedimented at 16,000 3 g
transferred to nitrocellulose. The blots were then incubated with a for 20 min at 48C, and the supernatant was collected and stored at
polyclonal, affinity-purified, anti-peptide antibody (at a dilution of 2708C. Protein concentrations were determined using the Bradford
1:1000) that we have previously raised to rat VMAT2 (Peter et al., assay (BioRad).
1995). Since the antibody recognizes the C terminus of VMAT2, it Monoamines and metabolites were measured using high perfor-
has the potential to detect forms of the protein truncated at the N mance liquid chromatography coupled with electrochemical detec-
terminus that might persist despite the gene disruption. As a control, tion (HPLC-EC) on an ESA Coulochem II detector equipped with a
the blots were also incubated with a polyclonal antibody to the rat model 5011 analytical cell (ESA) set at an applied potential of 400
vesicular acetylcholine transporter (Gilmor et al., 1996) and with a mV and a Velosep RP-18 column (Applied Biosystems). The mobile
monoclonal antibodyto rat synaptophysin (p38; Sigma),both diluted phase contained 6.9 g/l NaH2PO4´H2O, 80 mg/l EDTA, 750 mg/l hep-
1:5000. After incubation with the primary antibody, the blots were tasulfonic acid, and 4% methanol, adjusted to pH 3.6 with phos-
incubated with the appropriate secondary antibodies conjugated to phoric acid. Norepinephrine, DOPAC, 5-HIAA, dopamine, HVA, and
peroxidase and the deposits visualized by enhanced chemilumines- serotonin were measured in 100 ml samples from the whole brain
cence (Amersham). homogenates injected in a 200 ml injection loop. The neurochemicals
eluted in the above order and the total processing time was 25 min.
The chromatography peaks of interest were compared to 10 pg/mlTransport Measurement
external standards injected in the HPLC on a daily basis.Transport assays were initiated by adding membrane extracts (50
mg protein) to 200 ml SH buffer containing 4 mM KCl, 2.5 mM MgSO4,
4 mM ATP, and 20 nM 3H-serotonin (DuPont NEN), either with or Primary Midbrain Neuronal Cultures and Stimulation
without 5 mM reserpine. The reactions were incubated at 298C for Postnatal mouse midbrain cultures were established as previously
varying time intervals and terminated by dilution into 3 ml cold SH described (Mena et al., 1997), except that the serum-free medium
buffer followed by filtration through Supor 200 membranes (Gelman). was supplemented with 10 ng/ml glial-derived neurotrophic factor
Filters were dried and the bound radioactivity measured by scintilla- (Intergen) and cortical astrocyte monolayers were derived from
tion counting in 2.5 ml of cytoscint (ICN). Background uptake was Sprague-Dawley rats (Rayport et al., 1992). Briefly, the ventral mid-
determined at 08C for 0 min. Transport activity was calculated using brain from 0±24 hr neonatal mice was dissected, the tissue from
a 2 min time point during which the rate of uptake remained linear each animal dissociated in papain for 2 hr in separate vials, and
(data not shown). The activity was measured using at least three 80,000 cells per culture plated on the astrocyte monolayer. Each
different membrane preparations for each genotype. animal yielded two to three cultures. One day after plating, cultures
were treated with 6.6 ng/ml 5-flurodioxyuridine in 16.4 ng/ml uridine
to suppress cell division. All experiments compared cultures derivedTetrabenazine Binding
Tetrabenazine binding was initiated by adding membrane extracts from the same litter. TH staining was performed as previously de-
scribed (Mena et al., 1997). For cell counts, all TH-stained cell bodies(80 mg protein) to 200 ml SH buffer containing 5 nM 3H-dihydrotetra-
benazine (Amersham), either with or without excess unlabeled tetra- in the dish were counted using differential interference contrast
(DIC) optics in an inverted microscope.benazine (100 mM). The reactions were incubated at 298C for 20 min
and terminated by dilution into 4 ml cold SH buffer containing 125 In unstimulated primary midbrain cultures, dopamine levels were
measured in both the medium and perchloric acid cell extractsmM unlabeled tetrabenazine, followed by filtration through Supor
200 membranes (Gelman). Filters were dried and the bound radioac- using HPLC with electrochemical detection, and the values were
combined to yield total dopamine. For depolarization-evoked re-tivity measured by scintillation counting in 2.5 ml of cytoscint (ICN).
Background binding was determined using the reaction solution lease of dopamine from primary midbrain neurons, the cultures were
incubated in elevated KCl (40 mM KCl, 112 mM NaCl, 1 mM NaH2PO4,alone without added membrane extracts. Tetrabenazine binding
was measured using at least three different membrane preparations 10 mM HEPES, 1.2 mM CaCl2, 1 mM MgCl2, and 25 mM glucose
[pH 7.4]) for 2 min, the medium was collected immediately, andfor each genotype.
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the released dopamine was measured by HPLC. For amphetamine- form dopamine from exogenously administered L-DOPA. J. Neural
Transm. 103, 1287±1294.evoked release, cultures were incubated with D-amphetamine (10
mM) for 30 min, the medium was collected immediately, and the Bruns, D., and Jahn,R. (1995). Real-time measurement of transmitter
released dopamine was measured using HPLC. To determine total release from single synaptic vesicles. Nature 377, 62±65.
dopamine in the stimulated cultures, the amount in perchloric acid Cases, O., Vitalis, T., Seif, I., De Maeyer, E., Sotelo, C., and Gaspar,
extracts from the cells immediately after stimulation was added to P. (1996). Lack of barrels in the somatosensory cortex of monoamine
the amount of dopamine released. oxidase A-deficient mice: role of a serotonin excess during the criti-
cal period. Neuron 16, 297±307.
Drug Studies Chen, K., and Shih, J.C. (1990). Monoamine oxidase A and B: Struc-
To determine whether the low brain dopamine and serotonin levels ture, function and behavior. In Catecholamines: Bridging Basic Sci-
in VMAT2-deficient mice resulted from metabolism by monoamine ence with Clinical Medicine, S. Goldstein, G. Eisenhofer, and R.
oxidase (MAO), the MAO-A inhibitor clorgyline (10 mg/kg) and the McCarty, eds. (San Diego: Academic Press), pp. 292±296.
nonselective MAO inhibitor pargyline (75 mg/kg) were administered
Cotzias, G.C., Papavasiliou, P.S., and Gellene, R. (1969). Modifica-subcutaneously to VMAT21/1 and VMAT22/2 mice within 24 hr after
tion of parkinsonismÐchronic treatment with levodopa. N. Engl. J.birth. Two hours after injection, monoamine and metabolite levels
Med. 180, 337±345.were measured in perchloric acid extracts from the brains of these
Di Chiara, G., and Imperato, A. (1988). Drugs abused by humansanimals.
preferentially increase synaptic dopamine concentrations in theTo assess the acute effects of amphetamine administration on
mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USAthe behavior of VMAT22/2 mice, we alternately injected them with
85, 5274±5278.(1) D-amphetamine (10 mg/kg, subcutaneously), (2) nomifensine (10
mg/kg, subcutaneously) followed 30 min later by D-amphetamine, Erickson, J.D., Eiden, L.E., and Hoffman, B.J. (1992). Expression
and (3) normal saline. The injections were started within 24 hr after cloning of a reserpine-sensitive vesicular monoamine transporter.
birth and repeated twice daily. One hour after each injection, the Proc. Natl. Acad. Sci. USA 89, 10993±10997.
mice were scored for the presence of either active suckling or milk Finn, J.P., and Edwards, R.H. (1997). Individual residues contribute
in the stomach. The injections were administered and the animals to multiple differences in ligand recognition between vesicular
scored by an investigator blind to the treatment. monoamine transporters 1 and 2. J. Biol. Chem. 272, 16301±16307.
To test whether chronic administration of amphetamine prolongs
Fishell, G., and van der Kooy, D. (1987). Pattern formation in thesurvival in VMAT22/2 mice, mutant pups were given either D-amphet-
striatum: developmental changes in the distribution of striatonigralamine (10 mg/kg, subcutaneously) or normal saline three times a
neurons. J. Neurosci. 7, 1969±1978.day (8 a.m., 4 p.m., and 10 p.m.). Because newborn animals were
Florin, S.M., Kuczenski, R., and Segal, D.S. (1995). Effects of reser-alternately assigned to the two treatment groups at the time of
pine on extracellular caudate dopamine and hippocampus norepi-birth, both amphetamine and placebo-treated animals were present
nephrine responses to amphetamine and cocaine: mechanistic andtogether in most litters. Behavior, weight, and survival were moni-
behavioral considerations. J. Pharmacol. Exp. Ther. 274, 231±241.tored daily.
Frize, E.D. (1954). Mental depression in hypertensive patients
treated for long periods with high doses of reserpine. N. Engl. J.Statistical Analysis
Med. 251, 1006±1008.Statistical analysis was performed using the two-tailed Student's t
Gerfen, C.R. (1992). The neostriatal mosaic: multiple levels of com-test.
partmental organization in the basal ganglia. Annu. Rev. Neurosci.
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